Abstract
The number of deep-seated mycosis cases is increasing rapidly along with the extreme advanced technology and highly sophisticated treatment. High mortality of deep-seated mycosis is critical concern, and an appropriate strategy and usage of antifungals is extremely important. The increasing potential efficacy of antifungals using the technology of drug delivery system is one of the reasonable strategies for improving the outcome of these patients with fungal infection. The development of liposomal amphotericin B using liposome is considered as a successful model case of development of newer drugs to improve the potential antifungal activity and reduce the cytotoxic effect using drug delivery system. Other newer antifungal drugs using a variety of drug delivery technology are currently being developed and numerous studies are underway. The main aim of this review is to introduce these developing drugs and the future of management of deep-seated mycosis.
